Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combinatio...
Saved in:
Published in | Molecular cancer therapeutics Vol. 6; no. 9; pp. 2591 - 2599 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research
01.09.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells
through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types
of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin
could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced
apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented
quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells.
In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway,
as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the
cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor
stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies.
[Mol Cancer Ther 2007;6(9):2591–9] |
---|---|
AbstractList | Abstract
Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. [Mol Cancer Ther 2007;6(9):2591–9] Cytokines such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death receptors. Nevertheless, evading apoptosis induced by anticancer drugs characterizes many types of cancers. This results in the need for combination therapy. In this study, we have investigated whether the flavonoid quercetin could sensitize human colon adenocarcinoma cell lines to TRAIL-induced apoptosis. We report that quercetin enhanced TRAIL-induced apoptosis by causing the redistribution of DR4 and DR5 into lipid rafts. Nystatin, a cholesterol-sequestering agent, prevented quercetin-induced clustering of death receptors and sensitization to TRAIL-induced apoptosis in colon adenocarcinoma cells. In addition, our experiments show that quercetin, in combination with TRAIL, triggered the mitochondrial-dependent death pathway, as shown by Bid cleavage and the release of cytochrome c to the cytosol. Together, our findings propose that quercetin, through its ability to redistribute death receptors at the cell surface, facilitates death-inducing signaling complex formation and activation of caspases in response to death receptor stimulation. Based on these results, this study provides a challenging approach to enhance the efficiency of TRAIL-based therapies. [Mol Cancer Ther 2007;6(9):2591–9] |
Author | Lenka Doubravska Alexander Pintzas Ladislav Andera Faiy H. Psahoulia Konstantinos G. Drosopoulos |
Author_xml | – sequence: 1 givenname: Faiy H surname: Psahoulia fullname: Psahoulia, Faiy H organization: Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, 48 Vasileos Konstantinou Avenue, Athens 11635, Greece – sequence: 2 givenname: Konstantinos G surname: Drosopoulos fullname: Drosopoulos, Konstantinos G – sequence: 3 givenname: Lenka surname: Doubravska fullname: Doubravska, Lenka – sequence: 4 givenname: Ladislav surname: Andera fullname: Andera, Ladislav – sequence: 5 givenname: Alexander surname: Pintzas fullname: Pintzas, Alexander |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17876056$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkE1v4yAQhlHVVdOvn9CKU_fkFmyDybGKuruVUq22yh0RGGIqx7iAVeW2P724jtQLg5hn3kHPBTrtfQ8I3VByTykTD5RVrGgor-5fVpuCNAUhhJ6g8_wuCsFoffp1n5kFuojxLQNiWdIztKCNaDhh_Bz9_zdC0JBcj6FvVa8h4s3r4_O62INxKoHBavBD8tFFnCHtO5_PCQxYQ9dFvD3khhm163c4tYCV1uN-7FRymfQWG1CpxQE05JjwldK5wRkclE3xCv2wqotwfayXaPPrabP6U6z__n5ePa4LXROWCsbrrea6bmxtKSy3zFBVNoJazbmqtVCmtGVlOKtMTYm1VlsmDDG1VawxqrpEd3PsEPz7CDHJvYvT_1UPfoySizIrEWUG2Qzq4GMMYOUQ3F6Fg6RETublZFVOVmU2L0kjJ_N57va4YNxmdd9TR9UZ-DkDrdu1Hy6AnC0GiKCCbiWXS1myJa0-AYpIkbM |
CitedBy_id | crossref_primary_10_1038_sj_bjc_6605794 crossref_primary_10_1093_carcin_bgq220 crossref_primary_10_1002_glia_22345 crossref_primary_10_5012_jkcs_2015_59_2_136 crossref_primary_10_1002_cai2_99 crossref_primary_10_4993_acrt_29_96 crossref_primary_10_1186_s12885_018_4959_4 crossref_primary_10_1007_s00018_010_0407_6 crossref_primary_10_3892_ijo_2014_2795 crossref_primary_10_1016_j_fct_2013_08_085 crossref_primary_10_1007_s10495_012_0759_5 crossref_primary_10_1007_s13402_014_0183_7 crossref_primary_10_1097_MCO_0b013e32831394b8 crossref_primary_10_3390_molecules25225319 crossref_primary_10_2174_1389557519666191009152007 crossref_primary_10_1016_j_bbamem_2014_01_021 crossref_primary_10_18632_oncotarget_14675 crossref_primary_10_1007_s12038_012_9198_2 crossref_primary_10_1371_journal_pone_0016241 crossref_primary_10_1002_biof_1112 crossref_primary_10_1016_j_bcp_2008_12_027 crossref_primary_10_3892_ijo_2012_1748 crossref_primary_10_1016_j_ejmech_2017_12_039 crossref_primary_10_1016_j_jff_2016_06_004 crossref_primary_10_3390_ph13110342 crossref_primary_10_1016_j_febslet_2009_02_014 crossref_primary_10_1155_2019_9051542 crossref_primary_10_1016_j_biopha_2019_109604 crossref_primary_10_1097_CAD_0000000000000213 crossref_primary_10_1016_j_lfs_2010_07_004 crossref_primary_10_1016_j_micron_2021_103152 crossref_primary_10_1002_med_20123 crossref_primary_10_3389_fphar_2022_860209 crossref_primary_10_3892_etm_2015_2536 crossref_primary_10_1016_j_mam_2009_12_002 crossref_primary_10_1111_nure_12051 crossref_primary_10_1016_j_freeradbiomed_2013_05_039 crossref_primary_10_1016_j_jff_2013_11_002 crossref_primary_10_1155_2013_731940 crossref_primary_10_1007_s10495_009_0397_8 crossref_primary_10_1039_C4MD00268G crossref_primary_10_3109_10715762_2012_690514 crossref_primary_10_1128_AAC_03599_14 crossref_primary_10_1371_journal_pone_0107165 crossref_primary_10_1002_med_21985 crossref_primary_10_1016_j_biotechadv_2015_12_014 crossref_primary_10_4161_cbt_19600 crossref_primary_10_1038_cddis_2012_29 crossref_primary_10_1177_1178223417749855 crossref_primary_10_1007_s00249_011_0786_0 crossref_primary_10_1002_ptr_5402 crossref_primary_10_1016_j_canlet_2008_03_046 crossref_primary_10_1016_j_canlet_2010_11_001 crossref_primary_10_1016_S1002_0721_12_60346_9 crossref_primary_10_1186_s12885_016_2606_5 crossref_primary_10_1016_j_cellsig_2023_110667 crossref_primary_10_1002_1873_3468_12863 crossref_primary_10_1007_s13318_023_00843_7 crossref_primary_10_13045_acupunct_2014027 crossref_primary_10_1155_2013_757628 crossref_primary_10_1097_CMR_0000000000000447 crossref_primary_10_1002_jcp_26640 crossref_primary_10_2174_1871520621666210624110547 crossref_primary_10_18632_oncotarget_2091 crossref_primary_10_1080_10408398_2020_1815171 crossref_primary_10_2174_1389201021666200226093202 crossref_primary_10_18632_oncotarget_6295 crossref_primary_10_33393_dti_2020_2185 crossref_primary_10_1016_j_lfs_2010_01_008 crossref_primary_10_1038_gene_2015_31 crossref_primary_10_3390_cancers11121948 crossref_primary_10_1002_jcp_28777 crossref_primary_10_1039_c2nr32181e crossref_primary_10_13181_mji_v25i3_1449 crossref_primary_10_3390_cells12242840 crossref_primary_10_3390_ijms231911746 crossref_primary_10_1080_10408398_2017_1344186 crossref_primary_10_1038_srep24049 crossref_primary_10_1258_ebm_2011_011004 crossref_primary_10_5352_JLS_2009_19_9_1209 crossref_primary_10_1002_ijc_26323 crossref_primary_10_3390_ijms19123787 crossref_primary_10_18632_oncotarget_3073 crossref_primary_10_1007_s00018_016_2164_7 crossref_primary_10_1097_CAD_0000000000000095 crossref_primary_10_3389_fphar_2017_00015 crossref_primary_10_2174_0929867330666230301121611 crossref_primary_10_1021_jm801001d crossref_primary_10_1038_onc_2012_164 crossref_primary_10_1089_ars_2012_4573 crossref_primary_10_1016_j_bcp_2023_115907 crossref_primary_10_1016_j_acthis_2016_11_003 crossref_primary_10_1371_journal_pone_0054577 crossref_primary_10_1016_j_jare_2021_11_008 crossref_primary_10_3109_10408363_2011_631268 crossref_primary_10_1038_cddis_2012_55 crossref_primary_10_7314_APJCP_2015_16_2_465 crossref_primary_10_1155_2017_4357165 crossref_primary_10_1155_2021_3157867 crossref_primary_10_3389_fphar_2017_00109 crossref_primary_10_1007_s10620_010_1191_8 crossref_primary_10_1007_s00018_016_2321_z crossref_primary_10_1016_j_ejca_2012_03_005 crossref_primary_10_1016_j_jchromb_2014_01_005 crossref_primary_10_3390_biom9110679 crossref_primary_10_3892_etm_2013_1285 crossref_primary_10_1016_j_drup_2015_02_001 crossref_primary_10_1002_jcp_26595 crossref_primary_10_1088_1757_899X_991_1_012107 crossref_primary_10_1093_nar_gku1131 crossref_primary_10_1016_j_cytogfr_2013_12_009 crossref_primary_10_1016_j_bbrc_2009_08_016 crossref_primary_10_1021_la801471e crossref_primary_10_2174_1570193X16666190723112623 crossref_primary_10_1080_01635581_2021_1900301 crossref_primary_10_1007_s00262_009_0732_5 crossref_primary_10_1111_febs_12347 crossref_primary_10_1016_j_bbrc_2013_08_040 crossref_primary_10_1093_carcin_bgp334 crossref_primary_10_3109_07357900902744486 crossref_primary_10_3390_ijms13077886 crossref_primary_10_3390_molecules26123483 crossref_primary_10_1194_jlr_TR119000439 crossref_primary_10_3390_molecules26051315 crossref_primary_10_1016_j_bcp_2020_113923 |
Cites_doi | 10.1016/S0092-8674(00)81590-1 10.1016/S1074-7613(00)80211-3 10.1038/sj.onc.1207970 10.1074/jbc.272.43.26953 10.1038/sj.onc.1202568 10.1093/embo-reports/kvf022 10.1093/ajcn/81.1.243S 10.1038/35008667 10.1158/1535-7163.MCT-05-0086 10.1016/S0014-5793(99)01544-6 10.1158/1078-0432.CCR-05-2365 10.1038/sj.cdd.4401088 10.1158/0008-5472.CAN-05-1494 10.1038/sj.onc.1206127 10.1074/jbc.M412483200 10.1038/sj.leu.2402338 10.1016/j.drup.2005.02.003 10.1074/jbc.271.22.12687 10.1126/science.277.5327.768 10.1016/S0092-8674(01)00472-X 10.1038/sj.onc.1206493 10.1038/sj.onc.1207520 10.1016/j.ejca.2004.12.020 10.1038/sj.onc.1208086 10.1002/jcb.21098 10.1093/carcin/bgl232 10.1038/nrc821 10.1038/35036052 10.1158/0008-5472.CAN-03-3648 10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F 10.1038/sj.bjc.6601707 10.1016/0168-9525(93)90209-Z 10.1038/ni1024 10.1074/jbc.M605934200 10.1093/emboj/17.6.1675 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1158/1535-7163.MCT-07-0001 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-8514 |
EndPage | 2599 |
ExternalDocumentID | 10_1158_1535_7163_MCT_07_0001 17876056 6_9_2591 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 08R 123 2WC 34G 39C 53G 55 5RE 5VS AAPBV ABFLS ABOCM ACIWK ACPRK ADACO ADBBV ADBIT AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 H13 H~9 IH2 KQ8 L7B MVM O0- OK1 P2P RCR RHF RHI WOQ X7M ZA5 --- .55 18M 2FS 3O- AAJMC ACGFO ADCOW AFHIN BR6 BTFSW CGR CUY CVF ECM EIF NPM QTD TR2 W8F WHG YBU ZGI ZXP AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c405t-564bc6c47f4f1e9b5d1a2781fc66a4c8ad2f23d653d410fffcf58d0d4fa57da3 |
ISSN | 1535-7163 |
IngestDate | Fri Oct 25 02:18:35 EDT 2024 Fri Aug 23 03:44:29 EDT 2024 Sat Sep 28 07:52:50 EDT 2024 Fri Jan 15 19:23:15 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c405t-564bc6c47f4f1e9b5d1a2781fc66a4c8ad2f23d653d410fffcf58d0d4fa57da3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 17876056 |
PQID | 68287682 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_68287682 crossref_primary_10_1158_1535_7163_MCT_07_0001 pubmed_primary_17876056 highwire_cancerresearch_6_9_2591 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 20070901 2007-Sep 2007-09-01 |
PublicationDateYYYYMMDD | 2007-09-01 |
PublicationDate_xml | – month: 09 year: 2007 text: 20070901 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular cancer therapeutics |
PublicationTitleAlternate | Mol Cancer Ther |
PublicationYear | 2007 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2022060804494485900_BIB9 2022060804494485900_BIB8 2022060804494485900_BIB7 2022060804494485900_BIB6 2022060804494485900_BIB5 2022060804494485900_BIB4 2022060804494485900_BIB3 2022060804494485900_BIB2 2022060804494485900_BIB21 2022060804494485900_BIB1 2022060804494485900_BIB22 2022060804494485900_BIB20 2022060804494485900_BIB25 2022060804494485900_BIB26 2022060804494485900_BIB23 2022060804494485900_BIB24 2022060804494485900_BIB29 2022060804494485900_BIB27 2022060804494485900_BIB28 2022060804494485900_BIB10 2022060804494485900_BIB32 2022060804494485900_BIB11 2022060804494485900_BIB33 2022060804494485900_BIB30 2022060804494485900_BIB31 2022060804494485900_BIB14 2022060804494485900_BIB36 2022060804494485900_BIB15 2022060804494485900_BIB37 2022060804494485900_BIB12 2022060804494485900_BIB34 2022060804494485900_BIB13 2022060804494485900_BIB35 2022060804494485900_BIB18 2022060804494485900_BIB19 2022060804494485900_BIB16 2022060804494485900_BIB38 2022060804494485900_BIB17 |
References_xml | – ident: 2022060804494485900_BIB3 – ident: 2022060804494485900_BIB13 doi: 10.1016/S0092-8674(00)81590-1 – ident: 2022060804494485900_BIB22 doi: 10.1016/S1074-7613(00)80211-3 – ident: 2022060804494485900_BIB23 doi: 10.1038/sj.onc.1207970 – ident: 2022060804494485900_BIB10 doi: 10.1074/jbc.272.43.26953 – ident: 2022060804494485900_BIB9 doi: 10.1038/sj.onc.1202568 – ident: 2022060804494485900_BIB16 doi: 10.1093/embo-reports/kvf022 – ident: 2022060804494485900_BIB27 doi: 10.1093/ajcn/81.1.243S – ident: 2022060804494485900_BIB11 doi: 10.1038/35008667 – ident: 2022060804494485900_BIB36 doi: 10.1158/1535-7163.MCT-05-0086 – ident: 2022060804494485900_BIB30 doi: 10.1016/S0014-5793(99)01544-6 – ident: 2022060804494485900_BIB26 doi: 10.1158/1078-0432.CCR-05-2365 – ident: 2022060804494485900_BIB31 doi: 10.1038/sj.cdd.4401088 – ident: 2022060804494485900_BIB37 doi: 10.1158/0008-5472.CAN-05-1494 – ident: 2022060804494485900_BIB19 doi: 10.1038/sj.onc.1206127 – ident: 2022060804494485900_BIB20 doi: 10.1074/jbc.M412483200 – ident: 2022060804494485900_BIB21 doi: 10.1038/sj.leu.2402338 – ident: 2022060804494485900_BIB34 doi: 10.1016/j.drup.2005.02.003 – ident: 2022060804494485900_BIB8 doi: 10.1074/jbc.271.22.12687 – ident: 2022060804494485900_BIB2 – ident: 2022060804494485900_BIB14 doi: 10.1126/science.277.5327.768 – ident: 2022060804494485900_BIB38 doi: 10.1016/S0092-8674(01)00472-X – ident: 2022060804494485900_BIB6 doi: 10.1038/sj.onc.1206493 – ident: 2022060804494485900_BIB25 doi: 10.1038/sj.onc.1207520 – ident: 2022060804494485900_BIB32 doi: 10.1016/j.ejca.2004.12.020 – ident: 2022060804494485900_BIB18 doi: 10.1038/sj.onc.1208086 – ident: 2022060804494485900_BIB7 doi: 10.1002/jcb.21098 – ident: 2022060804494485900_BIB5 doi: 10.1093/carcin/bgl232 – ident: 2022060804494485900_BIB15 doi: 10.1038/nrc821 – ident: 2022060804494485900_BIB33 doi: 10.1038/35036052 – ident: 2022060804494485900_BIB28 doi: 10.1158/0008-5472.CAN-03-3648 – ident: 2022060804494485900_BIB29 – ident: 2022060804494485900_BIB4 doi: 10.1002/(SICI)1097-0215(20000201)85:3<438::AID-IJC22>3.0.CO;2-F – ident: 2022060804494485900_BIB24 doi: 10.1038/sj.bjc.6601707 – ident: 2022060804494485900_BIB1 doi: 10.1016/0168-9525(93)90209-Z – ident: 2022060804494485900_BIB17 doi: 10.1038/ni1024 – ident: 2022060804494485900_BIB35 doi: 10.1074/jbc.M605934200 – ident: 2022060804494485900_BIB12 doi: 10.1093/emboj/17.6.1675 |
SSID | ssj0018921 |
Score | 2.3426425 |
Snippet | Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells
through engagement of death... Cytokines such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of death... Abstract Cytokines such as tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) can induce apoptosis in colon cancer cells through engagement of... |
SourceID | proquest crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 2591 |
SubjectTerms | Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - pathology apoptosis Apoptosis - drug effects BH3 Interacting Domain Death Agonist Protein - metabolism Caspases - drug effects Caspases - metabolism colon Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Cytochromes c - metabolism Cytosol - drug effects Cytosol - metabolism Death Domain Receptor Signaling Adaptor Proteins - metabolism Flow Cytometry Fluorescent Antibody Technique Humans Immunoblotting Immunoprecipitation lipid rafts Membrane Microdomains - drug effects Membrane Microdomains - metabolism Mitochondria - drug effects Mitochondria - metabolism quercetin Quercetin - pharmacology Receptors, TNF-Related Apoptosis-Inducing Ligand - metabolism Receptors, Tumor Necrosis Factor - metabolism TNF-Related Apoptosis-Inducing Ligand - pharmacology TRAIL Tumor Cells, Cultured - drug effects |
Title | Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts |
URI | http://mct.aacrjournals.org/content/6/9/2591.abstract https://www.ncbi.nlm.nih.gov/pubmed/17876056 https://search.proquest.com/docview/68287682 |
Volume | 6 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvY_dlVz3sLTiLbUm2H0PX0K1Jtw4X-iZkySKhrR1iu9A97W_s3-5IviWQscuLSRRHIvo-jr7jnAtC76mrXTcIiSN9whwCB5YT-glzqEqJngitlG3ftjhlx-fk8wW9GAx-bkUtVWUylt_35pX8D6owBriaLNl_QLabFAbgNeALV0AYrn-F8VllwlJKU_UjWxr4ilH8bfpp7th8EKMlxTpfl7kpOmLjza8Aa2lu3IzME_vCiE9wyivZJk0JKavrpqOX0ZHKKMQRWMV0bdvywCxXq_VKjTZC1zWgWmW7aPvstgtsZXZ1uv1rIZamBbtVrDOxuu1zIz5uTEcF-LCO-zupdSv8trzo-3-B3Afv_qa4tBPM0-yyO1WmJkunHhZqBUS_2XmgEXQRW70Npg64cf62kWZbXIy2DS6tm301hze8jfYfDNQkO3RTj69laYNuJ83KO4W4T7_w2fl8zuOji_gOuuuBDTPG8-Ss_4MqjLymFG89YZMcBst82LvIruxpS1H_3q2x8iZ-iB40fgme1iR7hAZp9hjdWzSRF0_Qj45ruOUa3uUa7riG4SbLNVxTAVuu4eQWt1zDQA68zTWca2y5hjuumVks17Dl2lMUz47iw2On6d7hSHACSocykkgmSaCJdtMoocoVXhC6WjImiAyF8rTnK0Z9RdyJ1lpqGqqJIlrQQAn_GTrI8ix9gbAfEZl4KpUe9UgQsQS8CpH4grkqTLTnDtG43Vu-rmu0cOvb0pAbMLgBgy8OYz6pgy2GCLcI8HojmspaS854xA2nhuhdiwwHg2v2SWRpXhWcmRYRcBmi5zVg_Zpw-DFwKF7-8buv0P2e-a_RQbmp0jcgbsvkraXZL7oaqtM |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quercetin+enhances+TRAIL-mediated+apoptosis+in+colon+cancer+cells+by+inducing+the+accumulation+of+death+receptors+in+lipid+rafts&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Psahoulia%2C+Faiy+H&rft.au=Drosopoulos%2C+Konstantinos+G&rft.au=Doubravska%2C+Lenka&rft.au=Andera%2C+Ladislav&rft.date=2007-09-01&rft.issn=1535-7163&rft.volume=6&rft.issue=9&rft.spage=2591&rft.epage=2599&rft_id=info:doi/10.1158%2F1535-7163.mct-07-0001&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon |